A new model developed by Michigan Medicine researchers could change treatment guidelines for nearly two-thirds of men with localized prostate cancer.
Michigan Medicine experts discuss whether active surveillance — close monitoring without immediate treatment — could reduce overtreatment for some thyroid, prostate and breast cancer patients.
A new review finds that a family history of prostate cancer should not automatically exclude low-risk patients from an active surveillance approach.
A novel strategy to target a genetic anomaly that occurs in half of all prostate cancers may provide a path for developing new therapies against it.
But among those diagnosed, treatment rates remain high, despite increasing evidence that surveillance may be an appropriate option.
A new study finds nearly 12 percent of men with advanced disease have a genetic mutation. As a result, the authors say every patient should be screened.